| abstract |
The invention has the beneficial pharmacological properties, in particular the groups R 1 , R 2 , R 3 , X, m and n according to claim 1, which bind to and modulate the activity of the GPR40 receptor. It relates to compounds of general formula (I) which are as follows: This compound is suitable for the treatment and prevention of diseases that can be affected by this receptor, for example metabolic diseases, in particular type 2 diabetes. The present invention further relates to novel intermediates useful in the synthesis of compounds of formula I. (I) |